Capital Raising, M&A, Buyouts, IPOs, Financial Structuring:
Breslin has a successful investment, advisory and transaction history with over 80 transactions, predominantly in Biotech and Pharma markets.
The secondary market broadens the opportunity set for private equity investors, corporates, and privates by providing liquidity and by offering a tool to rebalance and diversify portfolios.
In 2004, BRESLIN pioneered the execution of private equity secondary transactions in Europe and has since then handled the successful secondary exits of a number of portfolios for BAYER Pharma, followed by many more for industrial, financial and private investors with a volume of over $800m.
New Company Formation and Spin-Offs:
Spin-offs are an apt strategy for the formation of new companies to introduce their innovative technologies and products to industrial markets.
With its strong investment background, BRESLIN possesses the necessary know-how in offering guidance to academic and corporate spin-offs. Various spin-offs in Europe have been initiated and managed by BRESLIN.
Based on long-standing expertise and an extensive network within the Biotech and Pharma industries, BRESLIN provides valuable opportunities to its clients for business development, cooperation, in and out licensing, and assistance in strategic or operational processes.
With its specialized investment firm based in Zurich, Switzerland, BRESLIN has so far provided venture capital to well-known biopharmaceutical companies in Europe, namely Actelion, 4SC, and GPC. We are currently focusing on seed and early stage investments as well as on academic and industrial spin-offs.
Exited Portfolio Companies: